BeyondSpring (NASDAQ:BYSI) Posts Earnings Results, Beats Estimates By $0.52 EPS

BeyondSpring (NASDAQ:BYSI) announced its quarterly earnings data on Friday. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.52, FiscalAI reports.

BeyondSpring Stock Performance

Shares of BeyondSpring stock traded down $0.16 during trading hours on Friday, hitting $0.84. The company’s stock had a trading volume of 777,182 shares, compared to its average volume of 1,984,170. The business has a 50 day moving average price of $1.38 and a two-hundred day moving average price of $1.49. BeyondSpring has a 12-month low of $0.73 and a 12-month high of $2.44. The company has a market cap of $34.50 million, a PE ratio of -5.99 and a beta of 0.48.

Institutional Trading of BeyondSpring

An institutional investor recently bought a new stake in BeyondSpring stock. State Street Corp purchased a new position in BeyondSpring Inc. (NASDAQ:BYSI) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned 0.57% of BeyondSpring at the end of the most recent reporting period. Institutional investors own 40.29% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeyondSpring in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.